Page last updated: 2024-08-18

pyrroles and spd 502

pyrroles has been researched along with spd 502 in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's6 (66.67)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Drejer, J; Gouliaev, AH; Jensen, LH; Mathiesen, C; Moller, A; Nielsen, EO; Varming, T; Wätjen, F1
Dewar, D; Fowler, JH; McCracken, E; McCulloch, J; Morrison, S1
Blackburn-Munro, G; Bomholt, SF; Erichsen, HK1
Gajhede, M; Greenwood, JR; Kasper, C; Kastrup, JS; Kristensen, AS; Liljefors, T; Mirza, O; Olsen, L; Pickering, DS; Schousboe, A; Sigurskjold, BW; Wätjen, F1
Mathiesen, C; Møller, A; Nissinen, J; Pitkänen, A; Rønn, LC1
Almqvist, PM; Finnerup, NB; Gormsen, L; Jensen, TS1
Perucca, E1
Ben-Menachem, E; Møller, A; Rysgaard, K; Sabers, A; Wolf, P1
Keppel Hesselink, JM1

Reviews

1 review(s) available for pyrroles and spd 502

ArticleYear
What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate.
    Epilepsia, 2009, Volume: 50 Suppl 12

    Topics: Acetamides; Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Fructose; Humans; Lacosamide; Pyrroles; Pyrrolidinones; Rats; Receptors, AMPA; Status Epilepticus; Tetrahydroisoquinolines; Topiramate; Treatment Outcome

2009

Trials

2 trial(s) available for pyrroles and spd 502

ArticleYear
The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study.
    Anesthesia and analgesia, 2009, Volume: 108, Issue:4

    Topics: Adult; Aged; Analgesia; Anesthetics, Local; Chronic Disease; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Hyperalgesia; Infusions, Intravenous; Lidocaine; Male; Middle Aged; Neuralgia; Pain Measurement; Peripheral Nerve Injuries; Peripheral Nerves; Peripheral Nervous System Diseases; Pyrroles; Receptors, AMPA; Receptors, Kainic Acid; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Young Adult

2009
A prospective, randomized, multicentre trial for the treatment of refractory status epilepticus; experiences from evaluating the effect of the novel drug candidate, NS1209.
    Epilepsy research, 2013, Volume: 106, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials, Phase II as Topic; Drug Resistance; Endpoint Determination; Female; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Receptors, AMPA; Research Design; Status Epilepticus; Tetrahydroisoquinolines; Treatment Outcome

2013

Other Studies

6 other study(ies) available for pyrroles and spd 502

ArticleYear
SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 289, Issue:3

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Binding Sites; Binding, Competitive; Cell Membrane; Cells, Cultured; Cerebral Cortex; Electroshock; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glycine; Isoquinolines; Kainic Acid; Kinetics; Male; Membrane Potentials; Mice; Mice, Inbred Strains; Molecular Structure; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Pipecolic Acids; Pyrroles; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Seizures; Stereoisomerism; Tetrahydroisoquinolines

1999
Grey matter and white matter ischemic damage is reduced by the competitive AMPA receptor antagonist, SPD 502.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2002, Volume: 22, Issue:9

    Topics: Aldehydes; Animals; Brain Ischemia; Carotid Artery, External; Carotid Artery, Internal; Disease Models, Animal; Functional Laterality; Growth Inhibitors; Humans; Isoquinolines; Male; Oligodendroglia; Periaqueductal Gray; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Tetrahydroisoquinolines

2002
Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain.
    Neuropharmacology, 2004, Volume: 47, Issue:3

    Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Excitatory Amino Acid Antagonists; Male; Morphine; Narcotics; Pain; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Pyrroles; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Kainic Acid; Tetrahydroisoquinolines; Time Factors

2004
The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209.
    Journal of molecular biology, 2006, Apr-07, Volume: 357, Issue:4

    Topics: Animals; Binding Sites; Crystallography, X-Ray; Dimerization; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Hydrogen Bonding; Macromolecular Substances; Models, Molecular; Molecular Structure; Protein Structure, Quaternary; Pyrroles; Quinoxalines; Rats; Receptors, AMPA; Recombinant Proteins; Tetrahydroisoquinolines; Thermodynamics

2006
Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat.
    Epilepsy research, 2007, Volume: 74, Issue:1

    Topics: Amygdala; Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography; Hippocampus; Kainic Acid; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Status Epilepticus; Tetrahydroisoquinolines; Video Recording

2007
NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned.
    Drug development research, 2017, Volume: 78, Issue:2

    Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Epilepsy; Humans; Neuralgia; Pyrroles; Receptors, AMPA; Stroke; Tetrahydroisoquinolines; Treatment Outcome

2017